Efficacy and Safety of Lamivudine or Telbivudine in Preventing Mother-to-Child Transmission of Hepatitis B Virus: A Real-World Study

Table 1

Baseline clinical characteristics of pregnant women infected with hepatitis B virus among three groups.

Variable	LAM group ()	LdT group ()	Control group ()
Age (years)				0.107
Primigravida (, %)	290 (79.9)	1018 (79.3)	765 (78.2)	0.732
HBeAg positive (, %)	351 (96.7)	1257 (98.0)	962 (98.4)	0.159
Treatment experienced (, %)	10 (2.8)	38 (3.0)	29 (3.0)	0.967
ALT (U/L)	42 (8–572)	37 (6–493)	32 (5–404)	<0.001
Rate of abnormal ALT (%)	76 (20.9)	290 (22.6)	184 (18.8)	0.090
HBV DNA (log10 IU/mL)				<0.001

Values presented as or median (range), unless otherwise noted. ALT: alanine aminotransferase; HBeAg: hepatitis B e antigen; HBV: hepatitis B virus.